NPY and fatty liver disease: Furthermore, two of the animals in the semaglutide and NPY agonist-treated group received a highly selective Y2R agonist (NNC0165-1273) in addition to an unselective NPY receptor agonist (PYY3-36 or NNC0165-0020), which had an initially pronounced effect on weight loss [27] but not on liver steatosis (after eight weeks of treatment).